WHO ICTRP trial
A clinical trial to evaluate the effect of the anti-viral drug Valganciclovir in…
EUCTR2019-001083-30-SE · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2019-001083-30-SE |
|---|---|
| Public title | A clinical trial to evaluate the effect of the anti-viral drug Valganciclovir in brain tumor patients |
| Scientific title | A multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy of valganciclovir as add-on therapy in glioblastoma patients |
| Primary sponsor | Karolinska Institutet |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;Israel;Sweden |
| Conditions | Glioblastoma is an incurable brain tumor with very dismal prognosis. Substantial evidence demonstrates that cytomegalovirus (CMV) is present in 90-100% of malignant glioblastoma.We have observed that valganciclovir is well tolerated among… |
| Interventions | Product Name: valganciclovir Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use |
| Registration date | Mar 4, 2019 |
| Target size | 220 |
| Secondary IDs | VIGAS2 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: